 Following the pre-NDA meeting, the FDA has asked Travere Therapeutics Inc NASDAQ: TVTX to submit additional data for the sparsentan program in focal segmental glomerulosclerosis FSGS, characterized by scarring sclerosis in the kidney. The agency indicated that the available data from the interim assessment of the DUPLEX Phase 3 study would not be adequate to support an accelerated approval at this time. 